Gelonghui, March 18, 丨 Yisheng Biotechnology (01061.HK) announced that for the year ended December 31, 2023, the Group recorded a consolidated turnover of approximately HK$1,707 billion, an increase of 29.5% over the previous year. Accordingly, the Group's profit increased by 22.1% compared to 2022 to approximately HK$275.3 million, which was particularly hampered by the resulting withholding tax. After considering the full conversion of convertible loans, the basic and diluted earnings per share attributable to the owners of the company were HK$48.27 and HK46.90 cents, respectively.
The Group's vision is to become a great company with a sense of social responsibility. In terms of business strategy, the Group focuses on R&D, production and sale of the genetically engineered drug Alkaline Fibroblast Growth Factor (“rb-bFGF”). rbbFGF can promote the repair and regeneration of various cells. The Group's turnover mainly comes from the Ophthalmology Division (“Ophthalmology”) and the Surgery (Trauma Care and Rehabilitation) division (“Surgery”, including dermatology, stomatology and obstetrics and gynecology), while helping the Group expand new therapeutic areas in oncology, orthopedics and neurology through strategic investments.
The Group is further engaged in the marketing and sale of a range of products and medical devices (including Yixuan granules, soft hydrophilic contact lenses, ultrasonic glaucoma treatment devices, folding artificial vitreous balloons, UV phototherapy devices, Pineke absorbable dressings, and other medical devices for myopia prevention and control, such as eye adjustment training lights and speciality defocus custom glasses) to complement the Group's ophthalmology and surgical treatment business.